For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service at certain sites in the UK for patients who meet the eligibility criteria.
Here you can find out more about BRCA testing, what the AstraZeneca
Types of BRCA gene mutation
Patients with high grade serous (HGS) ovarian cancer have a ~20% chance of having a BRCA1/2 mutation.6 There are two types of BRCA mutation – germline and somatic.
Around 14% of patients with high grade serous ovarian cancer have a germline BRCA mutation and 6% of patients have a somatic BRCA mutation.6